Transform Olympus: Transforming into a Global Medtech Company
First written in FY2019. 8 of 22 entries say "Restated". Latest entry: 2026-08-07.
No other company in this theme has enough history to compare yet.
- 2026-08-07RestatedEarnings presentation
「As a company that achieves growth driven by its purpose, we will open up the future of endoscopic medicine.」
Reports progress during the quarter under the purpose-driven management strategy announced in November 2025, whose strategic pillars are growth through innovation, simplification, and responsible behavior. - FY2026ReframedAnnual report
「In November 2025, the Company announced a new management strategy centered on its purpose. Under this strategy, it aims to further evolve as a medtech company while pursuing both sustainable growth and improved profitability.」
The Company changed its strategic positioning from the previous management strategy based on Transform Olympus to the new purpose-centered management strategy announced in November 2025. - FY2025RestatedAnnual report
「Despite this environment, the Olympus Group continues to pursue its transformation into a global medtech company under the 3 priorities of patient safety and sustainability, innovation for growth, and productivity improvement, in line with the management strategy announced in May 2023.」
The Company has reaffirmed that it is continuing its transformation into a global medtech company under the management strategy announced in May 2023 and its 3 priorities. - FY2025-H1RestatedAnnual report
「Despite this environment, the Olympus Group continues to pursue its transformation into a global medtech company under the 3 priorities of patient safety and sustainability, innovation for growth, and productivity improvement, in line with the management strategy announced in May 2023.」
The Company reaffirmed the management strategy announced in May 2023 and its transformation into a global medtech company under the 3 priorities. - FY2024-Q3RestatedAnnual report
「Despite this environment, the Olympus Group continues to pursue its transformation into a global medtech company under the 3 priorities of patient safety and sustainability, innovation for growth, and productivity improvement, in line with the management strategy announced in May 2023.」
The Company reaffirmed that it is continuing its transformation into a global medtech company under the 3 priorities set out in the management strategy announced in May 2023. - FY2024-Q1RestatedAnnual report
「Despite this environment, the Olympus Group continues to pursue its transformation into a global medtech company under the 3 priorities of patient safety and sustainability, innovation for growth, and productivity improvement, in line with the management strategy announced in May 2023.」
The Company reaffirmed that it is continuing its transformation into a global medtech company in line with the new management strategy announced in May 2023. - FY2023ReframedAnnual report
「As a result of pursuing transformation over the past 3 years through the Focus and Simplify and Transform to Perform stages, the Company achieved the milestone of an operating margin exceeding 20% in the current consolidated fiscal year. Going forward, in the new Shift to Grow stage, the Company will focus on both growth and profitability, aiming to expand its market position in its key segments and ultimately improve patient experience and treatment outcomes.」
Following the transformation stage under Transform Olympus and the achievement of the milestone of an operating margin exceeding 20%, the Company shifted the strategic focus to the growth stage under Shift to Grow. - FY2023-Q2AdvancedAnnual report
「Based on this Management Strategy, the Company is actively investing management resources in the healthcare field, centered on its endoscopy and therapeutic solutions businesses, and working to strengthen the management foundation needed to achieve sustainable growth. Following its review, the Company concluded that transferring all shares in Evident to Bain Capital would be the optimal course for increasing the Olympus Group's corporate value and achieving autonomous, sustainable growth in the scientific solutions business.」
As part of its focus on the healthcare field under Transform Olympus, the Company transferred its scientific solutions business to Bain Capital, further clarifying its allocation of management resources to healthcare. - FY2023-Q1AdvancedAnnual report
「Despite this environment, the Olympus Group is continuing its initiatives for sustainable growth in line with the medium- to long-term management strategy announced in November 2019, with the aim of making a major advance toward becoming a truly global medtech company. Based on this Management Strategy, the Company is investing management resources in the healthcare field, centered on its endoscopy and therapeutic solutions businesses, and working to strengthen the management foundation needed to achieve sustainable growth. As part of this effort, on 1 April 2022 the Company implemented a company split under which its scientific solutions business was transferred to Evident Corporation, a newly established wholly owned subsidiary, to support the business's sustainable growth and improved profitability.」
The Company reaffirmed its investment of management resources in the healthcare field in line with its medium- to long-term management strategy and stated that it transferred its scientific solutions business to Evident on 1 April 2022. - FY2022ReframedAnnual report
「For the fiscal year ending March 2023, the Company aims to achieve an operating margin of more than 20% as a milestone and intends to make it a year in which the strategic phase shifts from transformation to growth.」
The Company redefined Transform Olympus as the phase of shifting from transformation to growth in the fiscal year ending March 2023, rather than the phase of advancing corporate transformation. - FY2022-Q3AdvancedAnnual report
「On 6 November 2019, the Company announced a management strategy for achieving sustainable growth as a truly global medical technology company (the "Management Strategy"). Based on this Management Strategy, the Company is investing management resources in the healthcare field, centered on its endoscopy and therapeutic solutions businesses, and working to strengthen the management foundation needed to achieve sustainable growth.」
The Company is continuing to focus on the healthcare field under Transform Olympus, including by spinning off its scientific solutions business and integrating supply chain functions. - FY2022-Q1RestatedAnnual report
「Despite this environment, the Olympus Group is advancing initiatives for sustainable growth in line with the corporate transformation plan Transform Olympus, announced in January 2019 with the aim of making a major advance toward becoming a truly global medtech company, and the medium- to long-term management strategy announced in November 2019 based on that plan.」
The Company has reaffirmed its policy of pursuing sustainable growth in line with Transform Olympus and the medium- to long-term management strategy based on it. - FY2021AdvancedAnnual report
「For the fiscal year ending March 2022, the Company views itself as having entered a phase of deepening its capabilities, moving beyond the transformation into a global medtech company, and will implement the following initiatives as it carries out its corporate transformation toward achieving the target levels set out in the management strategy announced in November 2019.」
For Transform Olympus, the Company moved from the transformation phase toward becoming a global medtech company into a phase of deepening its capabilities, identifying healthcare growth, improvements in its corporate structure, product development investment, and ESG as measures for the following fiscal year. - FY2021-Q3AdvancedAnnual report
「Under this agreement, the company completed the transfer of the shares on 1 January 2021.」
As a core measure under Transform Olympus, the Company completed the spin-off of its imaging business and the transfer of 95% of the business to JIP. - FY2021-Q2AdvancedAnnual report
「As part of this strategy, the Company has positioned the selection and concentration of its business portfolio as one of the core elements for business growth and improved profitability. On 30 September 2020, it entered into a definitive agreement with OJ Holdings Corporation, a special-purpose company established by JIP, concerning the transfer of 95% of the shares in the newly established wholly owned subsidiary that would succeed to the Company's imaging business through an absorption-type company split.」
Under Transform Olympus, the Company moved into the execution phase for selecting and concentrating its business portfolio, signing a definitive agreement to spin off the imaging business and transfer 95% of it. - FY2021-Q1RestatedAnnual report
「Despite this environment, the Olympus Group has announced the corporate transformation plan Transform Olympus, unveiled in January 2019, which aims to make a major advance toward becoming a truly global medtech company, together with the medium- to long-term management strategy based on it. This management strategy sets out the direction the Company aims to pursue over the long term, and the Company is advancing initiatives for sustainable growth.」
The Company has reaffirmed Transform Olympus and the medium- to long-term management strategy based on it as its long-term direction. - FY2020AdvancedAnnual report
「The fiscal year ending March 2021 is viewed as an excellent opportunity to accelerate the transformation into a truly global medtech company and achieve sustainable growth.」
For Transform Olympus, the Company outlined specific measures for the fiscal year ending March 2021, including portfolio selection and concentration, fixed-cost reform, the introduction of next-generation endoscopy systems, investment in new products, and more efficient research and development. - FY2020-Q2AdvancedAnnual report
「Amid this business environment, the group announced Transform Olympus in January 2019, a corporate transformation plan aimed at becoming a true global medical technology company, and in November 2019 announced a medium- to long-term management strategy based on Transform Olympus. This management strategy will change from the medium-term management plan announced in April 2016, the 2016 Basic Management Plan (16CSP), and sets out the direction the company aims to pursue over the long term. Going forward, we will advance initiatives for sustainable growth based on this management strategy.」
The Company announced a medium- to long-term management strategy based on Transform Olympus, setting out a long-term direction to replace 16CSP. - FY2020-Q1RestatedAnnual report
「In addition to operating its businesses based on the fundamental concepts of the five-year medium-term management plan beginning in the fiscal year ending March 2017, the 2016 Basic Management Plan (16CSP), namely the “Business to Specialist” Company and One Olympus, the group announced Transform Olympus in January 2019, a corporate transformation plan aimed at becoming a true global medical technology company, and is advancing initiatives for sustainable growth.」
The Company has reaffirmed Transform Olympus as its corporate transformation plan aimed at making a major advance toward becoming a truly global medical technology company. - FY2019First statedAnnual report
「Against this backdrop, the Olympus Group is steadily implementing the 2016 Management Basic Plan (16CSP), formulated in March 2016, while advancing initiatives for sustainable growth to realize the corporate transformation plan Transform Olympus, announced in January 2019.」
In addition to 16CSP, the Company announced the corporate transformation plan Transform Olympus and set out its goal of transforming into a truly global medtech company.